OCD - Nursing Case Study

Pathophysiology

• Primary mechanism: Dysfunction in the cortico-striato-thalamo-cortical (CSTC) circuit leads to abnormal signaling between brain regions, particularly the orbitofrontal cortex, anterior cingulate cortex, and striatum, resulting in the repetitive thoughts and behaviors characteristic of OCD.

• Secondary mechanism: Imbalance in neurotransmitters, especially serotonin, affects the CSTC circuit. This disruption in serotonin levels contributes to the persistence of obsessive thoughts and compulsive actions by altering mood and anxiety regulation.

• Key complication: Increased anxiety and stress from untreated OCD can lead to significant impairments in daily functioning, exacerbating the cycle of obsessions and compulsions and increasing the risk of comorbid conditions such as depression.

Patient Profile

Demographics:

32-year-old female, accountant

History:

• Key past medical history: History of generalized anxiety disorder, family history of OCD

• Current medications: Sertraline 100 mg daily, Alprazolam 0.5 mg as needed

• Allergies: Penicillin

Current Presentation:

• Chief complaint: Increasing compulsive checking behaviors despite medication

• Key symptoms: Excessive hand washing, repeated checking of locks and appliances, intrusive thoughts

• Vital signs: Blood pressure 140/90 mmHg, heart rate 96 bpm, temperature 98.6°F, respiratory rate 20 breaths per minute

Section 1

Change in Patient Status:

Two weeks following her initial presentation, the patient returns for a follow-up appointment. Despite adherence to her prescribed medication regimen, she reports that her compulsive behaviors have intensified. The frequency of her hand washing has increased, and she now spends several hours per day checking locks and appliances, significantly impacting her ability to function at work. Her vital signs reveal a slight elevation in blood pressure at 145/92 mmHg and a heart rate of 100 bpm, indicating increased physiological stress. During the assessment, she appears visibly anxious, with noticeable tremors in her hands and a heightened startle response.

The patient’s cognitive load from intrusive thoughts has led to difficulty concentrating, further affecting her performance as an accountant. She expresses frustration and embarrassment over her inability to control these behaviors, which is now affecting her personal relationships. The clinical team notes the potential for developing depressive symptoms, as she describes feelings of hopelessness and diminished interest in previously enjoyed activities. These observations suggest that the current pharmacological approach may be insufficient, highlighting the need for a comprehensive treatment plan that includes both pharmacological adjustments and cognitive-behavioral therapy (CBT) to address the increasing severity of her OCD symptoms.

The change in her clinical status necessitates a reassessment of her treatment strategy. Consideration might be given to optimizing her current medication regimen, potentially augmenting Sertraline with an atypical antipsychotic or increasing the dose under careful monitoring. The introduction of CBT could provide her with effective coping strategies to manage her compulsive behaviors and intrusive thoughts more effectively. These interventions aim to restore her daily functioning and improve her quality of life, mitigating the risk of further complications such as major depressive disorder. The next steps in her management will focus on these therapeutic modifications and close monitoring of her response to ensure a comprehensive approach to her care.

Section 2

Response to Interventions:

Two weeks after the adjustment in her treatment plan, the patient returns for another follow-up visit. The clinical team had previously increased the dose of Sertraline and introduced an atypical antipsychotic, Aripiprazole, to augment her medication regimen. Additionally, she began attending weekly cognitive-behavioral therapy (CBT) sessions. During the assessment, the patient reports some improvement in her ability to manage compulsive behaviors, although she still experiences frequent intrusive thoughts. She mentions that the CBT techniques have been somewhat helpful in reducing the time spent on compulsions, allowing her to regain a few hours each day for work-related tasks.

Her vital signs show a slight improvement, with blood pressure reading at 138/88 mmHg and a heart rate of 92 bpm, suggesting a reduction in physiological stress. However, she continues to exhibit mild tremors and reports feeling fatigued, which may be attributed to the medication adjustments. Despite these challenges, she expresses hopefulness about the new treatment plan and is motivated to continue working on her coping strategies.

Laboratory tests reveal stable liver and kidney function, indicating that the medication adjustments are well-tolerated at this stage. The patient's mood appears more stabilized, yet she acknowledges ongoing struggles with concentration and occasional feelings of sadness. The clinical team considers the possibility of adding a low-dose anxiolytic to address residual anxiety symptoms, but they decide to focus on monitoring her progress closely over the next few weeks. The emphasis remains on optimizing her current regimen and providing support through psychotherapy to sustain her recovery journey and prevent the onset of more severe complications.

Section 3

Two weeks following her last visit, the patient presents with new symptoms that suggest emerging complications. She reports an increase in fatigue and persistent mild tremors, which have begun to interfere more significantly with her daily activities. Her blood pressure is now 142/90 mmHg, and her heart rate has increased to 98 bpm, indicating a slight escalation in physiological stress. This change prompts the clinical team to reconsider the current medication regimen and its side effects, particularly the introduction of Aripiprazole, which may be contributing to these symptoms.

Additional laboratory tests are conducted to further evaluate her condition. These tests reveal an elevated fasting blood glucose level of 110 mg/dL, a new finding that suggests the beginning of metabolic changes possibly linked to the atypical antipsychotic. Her A1C level, however, remains within normal limits, which provides some reassurance but necessitates ongoing monitoring. The clinical team discusses the risks and benefits of continuing Aripiprazole, considering alternative options to manage her obsessive-compulsive symptoms without compromising her metabolic health.

The patient expresses concern about her increasing fatigue and questions whether it could be affecting her progress in therapy. Despite these challenges, she remains committed to her treatment and is open to exploring adjustments in her medication. The team decides to reduce the dose of Aripiprazole slightly and schedules more frequent follow-up appointments to closely monitor her response. They emphasize the importance of lifestyle modifications, such as a balanced diet and regular physical activity, to mitigate potential metabolic side effects while continuing to prioritize her mental health recovery.

Section 4

Two weeks after the adjustment in her medication regimen, the patient returns for a follow-up appointment. She reports a slight improvement in her fatigue, although the tremors persist, albeit with reduced intensity. Her blood pressure has decreased slightly to 138/88 mmHg, and her heart rate has stabilized at 90 bpm, suggesting a modest reduction in physiological stress. Despite these improvements, she continues to experience challenges with concentration and reports occasional episodes of anxiety that she believes may be affecting her cognitive-behavioral therapy sessions.

Additional diagnostic tests reveal that her fasting blood glucose level remains elevated at 108 mg/dL, indicating a continued risk for metabolic complications. Her lipid profile shows a slightly elevated LDL cholesterol level at 130 mg/dL, which was previously within normal range. This new finding prompts the clinical team to further evaluate her cardiovascular risk factors and underscores the importance of implementing lifestyle changes.

The team discusses the possibility of introducing metformin to help manage her metabolic profile while maintaining a focus on her mental health needs. They also explore non-pharmacological strategies, such as mindfulness and relaxation techniques, to support her in managing anxiety and improving adherence to therapy. The patient expresses willingness to incorporate these strategies and is reassured by the collaborative approach of her care team. As they outline a plan for ongoing monitoring and support, the team remains vigilant for any additional complications that may arise as her treatment progresses.

Section 5

Two weeks following the introduction of metformin and the integration of mindfulness techniques into her daily routine, the patient returns for another follow-up appointment. She reports a marginal improvement in her anxiety levels, stating that the mindfulness exercises have helped her manage stress more effectively. However, she also notes experiencing gastrointestinal discomfort, a common side effect of metformin, which has slightly impacted her adherence to the medication. Her primary care team evaluates her adherence strategies, ensuring she is taking the medication with meals to mitigate side effects.

New diagnostic results reveal an improvement in her metabolic profile, with fasting blood glucose levels decreasing to 98 mg/dL, indicating better glycemic control. Her LDL cholesterol has also decreased to 120 mg/dL, reflecting the positive impact of lifestyle modifications and pharmacotherapy. However, during the physical examination, the nurse notes an increase in the patient's resting heart rate to 100 bpm despite the previous stability, prompting concerns about her cardiovascular response to the current treatment regimen.

The care team deliberates on the potential causes of the increased heart rate, considering factors such as the anxiety episodes she continues to experience and the potential side effects of her medication. They decide to adjust the timing of her medication administration and explore additional relaxation techniques to further ease her anxiety. Continuous monitoring of her cardiovascular status is emphasized, and the patient is encouraged to further engage with her therapy sessions to address underlying anxiety triggers. The team remains attentive to the balance between addressing her metabolic and mental health needs, ensuring a comprehensive approach to her care.